On February 27, Beijing Hotgen Biotech Co.Ltd(688068) released the annual performance express of 2021, realizing an operating revenue of 5.372 billion yuan in 2021, with a year-on-year increase of 946.14%; The net profit attributable to the shareholders of the parent company was 2.193 billion yuan, a year-on-year increase of 185681%; Non net profit attributable to shareholders of the parent company was RMB 2.189 billion, with a year-on-year increase of 187882%; The basic earnings per share was 35.26 yuan, a year-on-year increase of 185889%.
The company said that the company’s performance increased significantly in 2021, mainly due to the development of the New Coronavirus 2019n-CoV antigen detection kit (anterior nasal cavity) and the New Coronavirus 2019n-CoV antigen detection kit (saliva) in the early 2021, and the two rapid detection reagent products of New Coronavirus antigen. It was earlier certified by the German Federal Institute of drugs and medical devices (bfarm) for free testing at home and applied to the local epidemic prevention demand in Germany. In the first half of the year, the company’s foreign trade orders increased explosively; In the second half of this year, the self testing products of New Coronavirus antigen developed by the company have obtained self testing registration / record of EU CE, main MHRA economies such as British MHRA and French ANSM. In the fourth quarter, the revenue of overseas covid-19 antigen testing products increased significantly.
